SCHEMBL7043671

SCHEMBL7043671

CCOC(=O)c1ncn([C@@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H]2OC(C)=O)n1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
MAPT P10636 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
THRB P10828 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HIF1A Q16665 1/20 0.49
CA1 P00915 12/20 0.47
CA2 P00918 12/20 0.47
CA9 Q16790 12/20 0.47
CA12 O43570 10/20 0.47
CA14 Q9ULX7 10/20 0.47
TSHR P16473 1/20 0.43
PRKCA P17252 1/20 0.42
AKT1 P31749 1/20 0.42
PTK2 Q05397 1/20 0.42
PRKAB2 O43741 1/20 0.42
PRKAG1 P54619 1/20 0.42
PRKAA2 P54646 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3314328 0.90 LMNA (0.55) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL5718815 0.90 LMNA (0.55) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL13320635 0.90 LMNA (0.55) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL5718816 0.90 LMNA (0.55) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL3314337 0.90 LMNA (0.55) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL13352083 0.90 LMNA (0.55) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL5566952 0.88 LMNA (0.52) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL1110907 0.88 LMNA (0.52) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL3313120 0.87 LMNA (0.52) LMNAALDH1A1TP53MAPTTDP1
SCHEMBL3313109 0.87 LMNA (0.52) LMNAALDH1A1TP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660854-B2 Reacting a 1,2,4-triazole-3-carboxylate and beta-D-ribo furanosyl-1,2,3,5-tetraacetate in the presence of a catalyst YUHAN CORPORATION (KR) 2003-12-09 US disclosed
US-20030120064-A1 Processes for preparing beta-D-ribofuranose derivatives YUHAN CORPORATION (KR) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120064-A1 Processes for preparing beta-D-ribofuranose derivatives UMPS, SBDS, SAMHD1 LMNA 2389/4885ALDH1A1 1360/4885TP53 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.